UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 1,262,560 Shares of CRISPR Therapeutics AG $CRSP

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 182.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,952,751 shares of the company’s stock after purchasing an additional 1,262,560 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 2.26% of CRISPR Therapeutics worth $66,452,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. SFE Investment Counsel grew its holdings in shares of CRISPR Therapeutics by 5.8% during the first quarter. SFE Investment Counsel now owns 6,507 shares of the company’s stock valued at $221,000 after buying an additional 355 shares during the last quarter. Axxcess Wealth Management LLC grew its holdings in shares of CRISPR Therapeutics by 4.0% during the first quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company’s stock valued at $351,000 after buying an additional 393 shares during the last quarter. GF Fund Management CO. LTD. grew its holdings in shares of CRISPR Therapeutics by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company’s stock valued at $74,000 after buying an additional 394 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of CRISPR Therapeutics by 9.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,725 shares of the company’s stock valued at $195,000 after buying an additional 473 shares during the last quarter. Finally, SVB Wealth LLC purchased a new stake in CRISPR Therapeutics in the first quarter valued at $25,000. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Up 0.7%

Shares of CRSP stock opened at $56.26 on Monday. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $71.13. The stock has a market capitalization of $5.12 billion, a PE ratio of -10.36 and a beta of 1.81. The firm has a 50 day moving average of $56.73 and a two-hundred day moving average of $45.74.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.18. The business had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The company’s revenue for the quarter was up 72.5% on a year-over-year basis. During the same period in the previous year, the company earned ($1.49) EPS. Analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on CRSP shares. Royal Bank Of Canada raised their price target on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a “sector perform” rating in a research note on Tuesday, August 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $105.00 price target on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Chardan Capital reaffirmed a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, August 5th. HC Wainwright raised their price target on shares of CRISPR Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, August 7th. Finally, Barclays raised their price target on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $71.60.

Insider Buying and Selling

In related news, Director Simeon George purchased 989,812 shares of the business’s stock in a transaction that occurred on Wednesday, July 16th. The shares were purchased at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the purchase, the director directly owned 1,730,179 shares of the company’s stock, valued at $90,021,213.37. The trade was a 133.69% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.10% of the stock is owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.